Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/94801
Title:
Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.
Authors:
Woll, Penella J; Basser, R; Le Chevalier, T; Drings, P; Perez Manga, G; Adenis, A; Seymour, L; Smith, F; Thatcher, Nick
Abstract:
Raltitrexed, a thymidylate synthase inhibitor, was given to 21 patients with advanced small-cell lung cancer, at a dose of 3 mg m(-2) as a 15-min intravenous infusion at 21-day intervals. All of the patients had extensive disease and 17 had received prior therapy. Patients with disease refractory to primary chemotherapy were excluded. Forty-one treatment cycles were given (median two, range one to four). The drug was well tolerated. No objective tumour response was documented. The patients had chemoresistant disease, as shown by a response in only one of ten patients who went on to receive alternative cytotoxic regimens. We conclude that raltitrexed given in this schedule is inactive as second line therapy for small-cell lung cancer.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester, UK.
Citation:
Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer. 1997, 76 (2):264-5 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
1997
URI:
http://hdl.handle.net/10541/94801
PubMed ID:
9231930
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorWoll, Penella Jen
dc.contributor.authorBasser, Ren
dc.contributor.authorLe Chevalier, Ten
dc.contributor.authorDrings, Pen
dc.contributor.authorPerez Manga, Gen
dc.contributor.authorAdenis, Aen
dc.contributor.authorSeymour, Len
dc.contributor.authorSmith, Fen
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-03-24T12:59:05Z-
dc.date.available2010-03-24T12:59:05Z-
dc.date.issued1997-
dc.identifier.citationPhase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer. 1997, 76 (2):264-5 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid9231930-
dc.identifier.urihttp://hdl.handle.net/10541/94801-
dc.description.abstractRaltitrexed, a thymidylate synthase inhibitor, was given to 21 patients with advanced small-cell lung cancer, at a dose of 3 mg m(-2) as a 15-min intravenous infusion at 21-day intervals. All of the patients had extensive disease and 17 had received prior therapy. Patients with disease refractory to primary chemotherapy were excluded. Forty-one treatment cycles were given (median two, range one to four). The drug was well tolerated. No objective tumour response was documented. The patients had chemoresistant disease, as shown by a response in only one of ten patients who went on to receive alternative cytotoxic regimens. We conclude that raltitrexed given in this schedule is inactive as second line therapy for small-cell lung cancer.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshDisease Progression-
dc.subject.meshEnzyme Inhibitors-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshQuinazolines-
dc.subject.meshSurvival Rate-
dc.subject.meshThiophenes-
dc.subject.meshThymidylate Synthase-
dc.subject.meshTreatment Outcome-
dc.titlePhase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.